Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Protein Kinase Inhibitors"" wg kryterium: Temat


Tytuł:
Generating Potential RET-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Autorzy:
Liu L; Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130061, China.
Zhao X; Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130061, China.
Huang X; Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130061, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 17; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/chemistry
Proto-Oncogene Proteins c-ret*/antagonists & inhibitors
Humans ; Molecular Dynamics Simulation
Czasopismo naukowe
Tytuł:
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Autorzy:
Ezzati S; California Northstate University College of Medicine, Elk Grove, CA 95757, USA.
Salib S; California Northstate University College of Medicine, Elk Grove, CA 95757, USA.
Balasubramaniam M; Reynolds Institute on Aging, Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Aboud O; Department of Neurology, Department of Neurological Surgery, Comprehensive Cancer Center, University of California, Davis, Sacramento, CA 95817, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 15; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Brain Neoplasms*/drug therapy
ErbB Receptors*/antagonists & inhibitors
Glioblastoma*/drug therapy
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Adult ; Humans ; Precision Medicine ; Signal Transduction
Czasopismo naukowe
Tytuł:
Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation.
Autorzy:
Wang S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Xu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Pan C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Guo Q; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Li Q; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Wan S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Li Z; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Zhang J; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Wu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 04; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/isolation & purification
Antineoplastic Agents*/pharmacology
ErbB Receptors*/antagonists & inhibitors
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/isolation & purification
Protein Kinase Inhibitors*/pharmacology
Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Cell Line, Tumor ; Cell Proliferation ; Lung Neoplasms/drug therapy ; Molecular Docking Simulation ; Molecular Dynamics Simulation
Czasopismo naukowe
Tytuł:
Degradation trumps mutations in cancer.
Autorzy:
Davis RE; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. 480-481. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Proteolysis*/drug effects
Cell Line, Tumor ; Mutation ; Humans
Czasopismo naukowe
Tytuł:
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Autorzy:
Montoya S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Bourcier J; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Noviski M; Nurix Therapeutics, San Francisco, CA, USA.
Lu H; Nurix Therapeutics, San Francisco, CA, USA.
Thompson MC; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chirino A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Jahn J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Sondhi AK; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Gajewski S; Nurix Therapeutics, San Francisco, CA, USA.
Tan YSM; Nurix Therapeutics, San Francisco, CA, USA.
Yung S; Nurix Therapeutics, San Francisco, CA, USA.
Urban A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Wang E; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Han C; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Mi X; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kim WJ; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sievers Q; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Auger P; Nurix Therapeutics, San Francisco, CA, USA.
Bousquet H; Nurix Therapeutics, San Francisco, CA, USA.
Brathaban N; Nurix Therapeutics, San Francisco, CA, USA.
Bravo B; Nurix Therapeutics, San Francisco, CA, USA.
Gessner M; Nurix Therapeutics, San Francisco, CA, USA.
Guiducci C; Nurix Therapeutics, San Francisco, CA, USA.
Iuliano JN; Nurix Therapeutics, San Francisco, CA, USA.
Kane T; Nurix Therapeutics, San Francisco, CA, USA.
Mukerji R; Nurix Therapeutics, San Francisco, CA, USA.
Reddy PJ; Nurix Therapeutics, San Francisco, CA, USA.
Powers J; Nurix Therapeutics, San Francisco, CA, USA.
Sanchez Garcia de Los Rios M; Nurix Therapeutics, San Francisco, CA, USA.
Ye J; Nurix Therapeutics, San Francisco, CA, USA.
Barrientos Risso C; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Tsai D; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pardo G; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Notti RQ; Laboratory of Molecular Electron Microscopy, Rockefeller University, New York, NY, USA.
Pardo A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Affer M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Nawaratne V; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Totiger TM; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pena-Velasquez C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rhodes JM; Division of Hematology-Oncology, Department of Medicine at Zucker School of Medicine at Hofstra/Northwell, CLL Research and Treatment Center, Lake Success, NY, USA.
Zelenetz AD; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alencar A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Roeker LE; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mehta S; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
Garippa R; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
Linley A; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Soni RK; Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Skånland SS; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Brown RJ; Nurix Therapeutics, San Francisco, CA, USA.
Mato AR; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hansen GM; Nurix Therapeutics, San Francisco, CA, USA.
Abdel-Wahab O; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Taylor J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. eadi5798. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Agammaglobulinaemia Tyrosine Kinase*/genetics
Agammaglobulinaemia Tyrosine Kinase*/metabolism
Ikaros Transcription Factor*/metabolism
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Proteolysis*/drug effects
Drug Resistance, Neoplasm*/drug effects
Humans ; Mutation ; Phosphorylation ; Signal Transduction
Czasopismo naukowe
Tytuł:
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.
Autorzy:
Shan KS; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Rehman TU; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Ivanov S; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Domingo G; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Raez LE; Memorial Health Care, Thoracic Oncology Program, Pembroke Pines, FL 33328, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 03; Vol. 25 (1). Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Melanoma*/drug therapy
Melanoma*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Humans ; Mitogen-Activated Protein Kinase Kinases ; Mitogen-Activated Protein Kinases ; Molecular Targeted Therapy ; Proto-Oncogene Proteins B-raf/genetics
Czasopismo naukowe
Tytuł:
In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer.
Autorzy:
Chang CD; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chao MW; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.; Institute of Biopharmaceutical Sciences, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
Lee HY; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.
Liu YT; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Tu HJ; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Lien ST; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Lin TE; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Sung TY; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
Yen SC; Warshel Institute for Computational Biology, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, People's Republic of China.
Huang SH; Graphen Inc, New York, NY, USA.
Hsu KC; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan.; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Pan SL; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2166039.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/enzymology
Protein Serine-Threonine Kinases*/antagonists & inhibitors
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Humans ; Cell Line, Tumor ; Gemcitabine/chemistry ; Gemcitabine/pharmacology ; Intracellular Signaling Peptides and Proteins ; Computer Simulation ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations.
Autorzy:
Malarz K; Institute of Physics, University of Silesia in Katowice, Chorzów, Poland.
Mularski J; Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.
Pacholczyk M; Department of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland.
Musiol R; Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2201410.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/chemistry
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/chemistry
Molecular Docking Simulation ; Quinazolines/pharmacology
Czasopismo naukowe
Tytuł:
Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.
Autorzy:
Chen W; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Park JI; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 02; Vol. 24 (19). Date of Electronic Publication: 2023 Oct 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Proto-Oncogene Proteins B-raf*/metabolism
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
MAP Kinase Kinase 1/genetics ; Cell Line, Tumor ; Signal Transduction ; Drug Resistance, Neoplasm/genetics ; Mutation
Czasopismo naukowe
Tytuł:
Clinical outcomes of ALK + non-small cell lung cancer in Denmark.
Autorzy:
Hansen KH; Department of Oncology, Odense University Hospital, Odense, Denmark.
Johansen JS; Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Urbanska EM; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Meldgaard P; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Hjorth-Hansen P; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
Kristiansen C; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Stelmach M; Department of Oncology, Næstved Hospital, Næstved, Denmark.
Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Ulhøi MP; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Dydensborg AB; Takeda Pharma A/S, Copenhagen, Denmark.
Dünweber C; Takeda Pharma A/S, Copenhagen, Denmark.
Andersen JL; Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Pokaż więcej
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Dec; Vol. 62 (12), pp. 1775-1783. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Anaplastic Lymphoma Kinase*/antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/mortality
Lung Neoplasms*/drug therapy
Lung Neoplasms*/epidemiology
Lung Neoplasms*/metabolism
Protein Kinase Inhibitors*/therapeutic use
Female ; Humans ; Middle Aged ; Crizotinib/therapeutic use ; Denmark/epidemiology ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR :: ABL1 transcripts in tyrosine kinase inhibitor treated CML.
Autorzy:
Kongruang A; Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Limsuwanachot N; Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Magmuang S; Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Areesirisuk P; Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Niparuck P; Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Siriboonpiputtana T; Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Rerkamnuaychoke B; Human Genetic Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2256199.
Typ publikacji:
Journal Article
MeSH Terms:
Tyrosine Kinase Inhibitors*
Protein Kinase Inhibitors*/therapeutic use
Humans ; Real-Time Polymerase Chain Reaction ; Neoplasm, Residual
Czasopismo naukowe
Tytuł:
New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Autorzy:
Fakhry MM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt.
Mattar AA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt.
Alsulaimany M; Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina 42353, Saudi Arabia.
Al-Olayan EM; Department of Zoology, College of Science, King Saud University, Riyadh 11495, Saudi Arabia.
Al-Rashood ST; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abdel-Aziz HA; Applied Organic Chemistry Department, National Research Center, Cairo 12622, Egypt.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Nov 06; Vol. 28 (21). Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/chemistry
Antineoplastic Agents*/chemistry
Humans ; Molecular Structure ; Structure-Activity Relationship ; Lapatinib/pharmacology ; Drug Screening Assays, Antitumor ; Cell Proliferation ; ErbB Receptors/metabolism ; Molecular Docking Simulation ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies.
Autorzy:
Alrouji M; Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, 11961, Shaqra, Saudi Arabia.
Benjamin LS; College of Nursing, King Khalid University (KKU), Abha, Kingdom of Saudi Arabia.
Alhumaydhi FA; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, 52571, Buraydah, Saudi Arabia.
Al Abdulmonem W; Department of Pathology, College of Medicine, Qassim University, Buraydah, Saudi Arabia.
Baeesa SS; Division of Neurosurgery, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Rehan M; King Fahd Medical Research Center, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Shahwan M; College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE.; Center for Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, UAE.
Shamsi A; Center for Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, UAE. .
Akhtar A; Department of Pharmacognosy, College of Pharmacy, King Khalid University (KKU), Guraiger St., 62529, Abha, Saudi Arabia. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 17; Vol. 13 (1), pp. 17684. Date of Electronic Publication: 2023 Oct 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors
Drug Repositioning*
Molecular Dynamics Simulation*
Protein Kinase Inhibitors*/therapeutic use
Humans ; Drug Discovery ; Molecular Docking Simulation
Czasopismo naukowe
Tytuł:
The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism.
Autorzy:
Leow BCS; Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA, 5000, Australia.; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, 5000, Australia.
Kok CH; Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA, 5000, Australia.; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, 5000, Australia.
Yeung DT; Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA, 5000, Australia.; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, 5000, Australia.; Australasian Leukaemia & Lymphoma Group, Richmond, VIC, 3121, Australia.; Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Hughes TP; Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA, 5000, Australia.; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, 5000, Australia.; Australasian Leukaemia & Lymphoma Group, Richmond, VIC, 3121, Australia.; Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
White DL; Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA, 5000, Australia.; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, 5000, Australia.; Australasian Leukaemia & Lymphoma Group, Richmond, VIC, 3121, Australia.; Australian & New Zealand Children's Haematology/Oncology Group, Clayton, VIC, 3168, Australia.; Australian Genomics Health Alliance, Parkville, VIC, 3052, Australia.
Eadie LN; Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA, 5000, Australia. .; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, 5000, Australia. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Aug 11; Vol. 13 (1), pp. 13110. Date of Electronic Publication: 2023 Aug 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Fusion Proteins, bcr-abl*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Dasatinib/pharmacology ; Drug Resistance, Neoplasm/genetics ; Mutation
Czasopismo naukowe
Tytuł:
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies.
Autorzy:
Nitulescu GM; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Stancov G; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Seremet OC; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Nitulescu G; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Mihai DP; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Duta-Bratu CG; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Barbuceanu SF; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Olaru OT; Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Jul 12; Vol. 28 (14). Date of Electronic Publication: 2023 Jul 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Pyrazoles*/chemistry
Pyrazoles*/pharmacology
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/classification
Protein Kinase Inhibitors*/pharmacology
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Drug Design*
Structure-Activity Relationship ; Humans ; Animals
Czasopismo naukowe
Tytuł:
Tyrosine Kinase Inhibitor Profiling Using Multiple Forskolin-Responsive Reporter Cells.
Autorzy:
Kasahara Y; Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan.
Tamamura S; Japan Biological Informatics Consortium (JBiC), 2-45 Aomi, Koto-ku, Tokyo 135-8073, Japan.
Hiyama G; Translational Research Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Takagi M; Translational Research Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Nakamichi K; Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan.
Doi Y; Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan.
Semba K; Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan.; Translational Research Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Watanabe S; Translational Research Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Ishikawa K; Japan Biological Informatics Consortium (JBiC), 2-45 Aomi, Koto-ku, Tokyo 135-8073, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 08; Vol. 24 (18). Date of Electronic Publication: 2023 Sep 08.
Typ publikacji:
Journal Article
MeSH Terms:
Tyrosine Kinase Inhibitors*
Protein Kinase Inhibitors*/pharmacology
Humans ; Dasatinib/pharmacology ; Colforsin/pharmacology ; Imatinib Mesylate/pharmacology
Czasopismo naukowe
Tytuł:
Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors.
Autorzy:
Xerxa E; LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany.
Laufkötter O; LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany.
Bajorath J; LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Aug 01; Vol. 28 (15). Date of Electronic Publication: 2023 Aug 01.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/pharmacology
Protein Kinases*
Phosphorylation ; Drug Discovery
Czasopismo naukowe
Tytuł:
Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia.
Autorzy:
Wang JX; Nursing Department, General Hospital of Tianjin Medical University, Tianjin, China.; Division of Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Yang MM; Division of Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; School of Nursing, Tianjin Medical University, Tianjin, China.
Liu LP; Division of Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zhang HM; Division of Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Wang MC; Division of Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Chen YW; Division of Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zang XY; School of Nursing, Tianjin Medical University, Tianjin, China.
Hu F; Nursing Department, General Hospital of Tianjin Medical University, Tianjin, China.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Jul; Vol. 55 (3), pp. 1023-1030. Date of Electronic Publication: 2023 Feb 06.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Adolescent ; Humans ; Child ; Tyrosine Kinase Inhibitors ; Prognosis ; Medication Adherence
Czasopismo naukowe
Tytuł:
Granulomatous reaction to permanent eyebrow makeup successfully treated with oral tofacitinib.
Autorzy:
Sun YH; Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lao LM; Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Pokaż więcej
Źródło:
Journal of cosmetic dermatology [J Cosmet Dermatol] 2023 Jul; Vol. 22 (7), pp. 2131-2132. Date of Electronic Publication: 2023 Feb 10.
Typ publikacji:
Letter
MeSH Terms:
Eyebrows*
Protein Kinase Inhibitors*/adverse effects
Humans ; Piperidines ; Pyrimidines
Opinia redakcyjna
Tytuł:
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants.
Autorzy:
Ucpinar S; Department of Pharmacokinetics, Dynamics, and Metabolism, Sanofi US, Inc., Bridgewater, New Jersey, USA.
Smith PF; Integrated Drug Development, Certara, Parsippany, New Jersey, USA.
Long L; Clinical and Pharmaceutical Development, Kezar Life Sciences, South San Francisco, California, USA.
Li F; Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA.
Yan H; Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA.
Wadhwa J; Clinical and Pharmaceutical Development, Kezar Life Sciences, South San Francisco, California, USA.
Chu KA; Analytical and Pharmaceutical Development, Sanofi US, Inc., Bridgewater, New Jersey, USA.
Shu J; Principia Biopharma Inc., South San Francisco, California, USA.
Nunn P; Principia Biopharma Inc., South San Francisco, California, USA.
Li M; Department of Pharmacokinetics, Dynamics, and Metabolism, Sanofi US, Inc., Bridgewater, New Jersey, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Jul; Vol. 16 (7), pp. 1210-1219. Date of Electronic Publication: 2023 Apr 23.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Tyrosine Kinase Inhibitors*
Protein Kinase Inhibitors*/adverse effects
Humans ; Male ; Biological Availability ; Healthy Volunteers ; Carbon Radioisotopes ; Administration, Oral
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies